A

Apontis Pharma AG
XETRA:APPH

Watchlist Manager
Apontis Pharma AG
XETRA:APPH
Watchlist
Price: 11.25 EUR 2.27% Market Closed
Market Cap: 95.6m EUR

EV/EBITDA
Enterprise Value to EBITDA

-9.1
Current
2.3
Median
12.6
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-9.1
=
Enterprise Value
79.4m EUR
/
EBITDA
-8.7m EUR
EBITDA Growth EV/EBITDA to Growth
DE
A
Apontis Pharma AG
XETRA:APPH
Average EV/EBITDA: 435.2
Negative Multiple: -9.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
43.5
30%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.3
15%
1
CH
Roche Holding AG
SIX:ROG
11.9
8%
1.5
US
Merck & Co Inc
NYSE:MRK
9.3
9%
1
UK
AstraZeneca PLC
LSE:AZN
127.1
9%
14.1
CH
Novartis AG
SIX:NOVN
11.5
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
265.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.8
3%
2.9

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
22.9
2-Years Forward
EV/EBITDA
9.7
3-Years Forward
EV/EBITDA
5.8